Rumors of Takeover Surround Biotech Drugmaker InterMune

By Reuters

Mar 11, 2014

InterMune Inc., an orphan drug company that specializes in treating fatal scarring of the lungs, is attracting takeover interest from several large pharmaceutical companies, according to Reuter's sources.

Buyer interest has surged in recent weeks after InterMune announced positive late-stage trial results for pirfenidone, a that drug treats idiopathic pulmonary fibrosis.

InterMune has not commented regarding formal offers or bid prices, but current market value is estimated at $2.7 billion.

Read the Reuters press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments